1056PDPhase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression. (23rd October 2018) - Joerger, M; Takahashi, S; Sayehli, C M; Slosarczyk, S; Navarro Mendivil, A; Cassier, P A; Nogai, H; Zhang, C; Sei, F; Bender, S; Ellinghaus, P; Tahara, M